FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578287193> ?p ?o ?g. }

• W2578287193 abstract "Abstract Background: Dasatinib (SPRYCEL®, formerly BMS-354825) is a novel, oral, multitargeted kinase inhibitor of BCR-ABL, SRC, and other kinases that is approximately 300 times more potent than Imatinib in vitro. Dasatinib has been shown to be effective and safe in pts with CML resistant or intolerant to Imatinib, As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic with the standard dosage of 100 mg once daily. Data regarding tolerability in elderly pts are scanty The aim of this study is to test if escalated dasatinib dose up to 60 mg once daily is as effective as standard dose of 100 mg QD with a better toxicity profile in elderly patients with chronic myeloid leukemia in late chronic phase resistant to or intolerant of Imatinib. Patients and Methods: As of July 2007, 4 eligible patients have been enrolled and treated :4F ; median age 77 y [range 73–82]; 1 imatinib-resistant, 3 imatinib-intolerant). Dasatinib was given at 20 mg once daily (QD) starting dose with dose escalation to 40 mg QD or 60 mg QD in pts tolerant or lacking response. Complete blood counts were obtained weekly for the first 12 weeks; bone marrow cytology and cytogenetics every 1 months, and molecular monitoring of BCR-ABL transcript levels by real-time qPCR every 12 weeks. The primary endpoint was toxicity. Median time from diagnosis of CML was 62 months (range 36 – 88). Prior therapy included interferon-alpha in 1/4. 50 percent of pts had 400 mg of prior imatinib. 25% had 600 mg. 100 % of pts received imatinib for &gt;3 yrs. Best response to prior imatinib therapy was a CHR in 100, and partial (PCyR) cytogenetic responses in 75 % of pts. No BCR-ABL baseline mutations were found. Results: The analyses with a median follow-up of 12 months (7–12) months show hematologic toxicity (grade 3 thrombocytopenia and leukopenia) at 60 mg OD in 2 out 4 pts. Dose interruptions occurred in 1/4 pts at 60 mg One pts was intolerant to dasatinib and switched to HU Patients received an average daily dose of 40 mg/day (range 20–60 mg). Non-hematologic toxicity consisted mainly of grade 1 diarrhea, headache 2 patients experienced grade II muscolo-skeletal toxicity and fatigue at 60 mg/day.) 100% pts had a CHR, and 50% a PCyR. Conclusions: Dasatinib demonstrated substantial hematologic activity in elderly patients with late CP-CML. Despite the maximum dose reached was 60 mg QD only the 75% of pts were able to continued the treatment. because of toxicity. The novel TKIs therapies constitute an important therapeutic challenge in this particularly subset of patients when compared with younger patients" @default.
• W2578287193 created "2017-01-26" @default.
• W2578287193 creator A5009314518 @default.
• W2578287193 creator A5015532308 @default.
• W2578287193 creator A5016680918 @default.
• W2578287193 creator A5054709335 @default.
• W2578287193 creator A5067301044 @default.
• W2578287193 date "2008-11-16" @default.
• W2578287193 modified "2023-09-30" @default.
• W2578287193 title "09:00–09:05Escalated Dasatinib Dose up to 60 Mg O.D. in Elderly Patients with Chronic Myeloid Leukemia in Late Chronic Phase Resistant to or Intolerant of Imatinib-12 Months Follow-up" @default.
• W2578287193 doi "https://doi.org/10.1182/blood.v112.11.4283.4283" @default.
• W2578287193 hasPublicationYear "2008" @default.
• W2578287193 type Work @default.
• W2578287193 sameAs 2578287193 @default.
• W2578287193 citedByCount "0" @default.
• W2578287193 crossrefType "journal-article" @default.
• W2578287193 hasAuthorship W2578287193A5009314518 @default.
• W2578287193 hasAuthorship W2578287193A5015532308 @default.
• W2578287193 hasAuthorship W2578287193A5016680918 @default.
• W2578287193 hasAuthorship W2578287193A5054709335 @default.
• W2578287193 hasAuthorship W2578287193A5067301044 @default.
• W2578287193 hasConcept C126322002 @default.
• W2578287193 hasConcept C143998085 @default.
• W2578287193 hasConcept C197934379 @default.
• W2578287193 hasConcept C203092338 @default.
• W2578287193 hasConcept C2777583451 @default.
• W2578287193 hasConcept C2778375690 @default.
• W2578287193 hasConcept C2778729363 @default.
• W2578287193 hasConcept C2779536868 @default.
• W2578287193 hasConcept C29730261 @default.
• W2578287193 hasConcept C3019892230 @default.
• W2578287193 hasConcept C535046627 @default.
• W2578287193 hasConcept C71924100 @default.
• W2578287193 hasConcept C90924648 @default.
• W2578287193 hasConcept C98274493 @default.
• W2578287193 hasConceptScore W2578287193C126322002 @default.
• W2578287193 hasConceptScore W2578287193C143998085 @default.
• W2578287193 hasConceptScore W2578287193C197934379 @default.
• W2578287193 hasConceptScore W2578287193C203092338 @default.
• W2578287193 hasConceptScore W2578287193C2777583451 @default.
• W2578287193 hasConceptScore W2578287193C2778375690 @default.
• W2578287193 hasConceptScore W2578287193C2778729363 @default.
• W2578287193 hasConceptScore W2578287193C2779536868 @default.
• W2578287193 hasConceptScore W2578287193C29730261 @default.
• W2578287193 hasConceptScore W2578287193C3019892230 @default.
• W2578287193 hasConceptScore W2578287193C535046627 @default.
• W2578287193 hasConceptScore W2578287193C71924100 @default.
• W2578287193 hasConceptScore W2578287193C90924648 @default.
• W2578287193 hasConceptScore W2578287193C98274493 @default.
• W2578287193 hasLocation W25782871931 @default.
• W2578287193 hasOpenAccess W2578287193 @default.
• W2578287193 hasPrimaryLocation W25782871931 @default.
• W2578287193 hasRelatedWork W2002984005 @default.
• W2578287193 hasRelatedWork W2265610056 @default.
• W2578287193 hasRelatedWork W2485410755 @default.
• W2578287193 hasRelatedWork W2522656204 @default.
• W2578287193 hasRelatedWork W2530803155 @default.
• W2578287193 hasRelatedWork W2538709448 @default.
• W2578287193 hasRelatedWork W2552199157 @default.
• W2578287193 hasRelatedWork W2559167495 @default.
• W2578287193 hasRelatedWork W2559459637 @default.
• W2578287193 hasRelatedWork W2564253402 @default.
• W2578287193 hasRelatedWork W2565606062 @default.
• W2578287193 hasRelatedWork W2566727098 @default.
• W2578287193 hasRelatedWork W2580067970 @default.
• W2578287193 hasRelatedWork W2583320244 @default.
• W2578287193 hasRelatedWork W2587686701 @default.
• W2578287193 hasRelatedWork W2587824345 @default.
• W2578287193 hasRelatedWork W2589984089 @default.
• W2578287193 hasRelatedWork W2597372376 @default.
• W2578287193 hasRelatedWork W2979395636 @default.
• W2578287193 hasRelatedWork W2994484228 @default.
• W2578287193 isParatext "false" @default.
• W2578287193 isRetracted "false" @default.
• W2578287193 magId "2578287193" @default.
• W2578287193 workType "article" @default.